MANUK CHULYAN: Open Payments
NPI 1881986826 · GLENDALE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$353 in 14 payments from 10 companies in 2025. Trend: 2023 $727 · 2024 $516 · 2025 $353
Food & beverage: $353
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 2 | $66 |
| Ardelyx, Inc. | 2 | $53 |
| AstraZeneca Pharmaceuticals LP | 2 | $51 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $39 |
| Aimmune Therapeutics, Inc. | 1 | $34 |
| Lilly USA, LLC | 1 | $33 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| PFIZER INC. | 1 | $16 |
| Novo Nordisk Inc | 1 | $15 |
Products named: IBSRELA, BREZTRI, Kerendia, ZENPEP, MOUNJARO, GEMTESA, GVOKE HYPOPEN, NURTEC ODT.
Industry payments across CA — which companies pay providers there.
